4.4 Article

The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice

期刊

NEUROGASTROENTEROLOGY AND MOTILITY
卷 25, 期 8, 页码 E550-E559

出版社

WILEY
DOI: 10.1111/nmo.12158

关键词

abdominal pain; cannabinoid receptor inverse agonist; constipation; endogenous cannabinoid system; irritable bowel syndrome

资金

  1. Deutsche Forschungsgemeinschaft (DFG) [STO645-6/1]
  2. University of Calgary Research Grant committee
  3. Iuventus Plus program of the Polish Ministry of Science and Higher Education [0119/IP1/2011/71, IP2012 010772]
  4. National Natural Science Foundation of China (NSFC) Research Fund for International Young Scientists [81250110087]

向作者/读者索取更多资源

Background Constipation-predominant irritable bowel syndrome (IBS-C) is a common functional gastrointestinal (GI) disorder with abdominal pain and decreased motility. Current treatments of IBS-C are insufficient. The aim of this study was to evaluate the potential application of taranabant, a cannabinoid type 1 (CB1) inverse agonist using mouse models mimicking the symptoms of IBS-C. Methods Changes in intestinal contractile activity were studied in vitro, using isolated mouse ileum and colon and intracellular recordings. In vivo, whole gastrointestinal transit (WGT) and fecal pellet output (FPO) were measured under standard conditions and with pharmacologically delayed GI transit. The antinociceptive effect was evaluated in mustard oil- and acetic acid-induced models of visceral pain. Forced swimming and tail suspension tests were performed and locomotor activity was measured to evaluate potential central side effects. Key Results In vitro, taranabant (10(-10)-10(-7)molL(-1)) increased contractile responses in mouse ileum and blocked the effect of the CB agonist WIN 55,212-2. Taranabant had no effect on the amplitude of electrical field stimulation (EFS)-evoked junction potentials. In vivo, taranabant (0.1-3mgkg(-1), i.p. and 3mgkg(-1), p.o.) increased WGT and FPO in mice and reversed experimental constipation. The effect of taranabant was absent in CB1(-/-) mice. Taranabant significantly decreased the number of pain-related behaviors in animal models. At the doses tested, taranabant did not display mood-related adverse side effects typical for CB1 receptor inverse agonists. Conclusions & Inferences Taranabant improved symptoms related to slow GI motility and abdominal pain and may become an attractive template in the development of novel therapeutics targeting IBS-C.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据